Crescita Therapeutics Inc (CTX) - Total Assets
Based on the latest financial reports, Crescita Therapeutics Inc (CTX) holds total assets worth CA$20.33 Million CAD (≈ $14.70 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check CTX cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Crescita Therapeutics Inc - Total Assets Trend (2014–2025)
This chart illustrates how Crescita Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Explore Crescita Therapeutics Inc long-term investment intensity to see how much of total assets are deployed in long-term investments.
Crescita Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Crescita Therapeutics Inc's total assets of CA$20.33 Million consist of 77.3% current assets and 22.7% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 42.2% |
| Accounts Receivable | CA$2.11 Million | 10.4% |
| Inventory | CA$4.72 Million | 23.2% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$1.46 Million | 7.2% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Crescita Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Crescita Therapeutics Inc market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Crescita Therapeutics Inc's current assets represent 77.3% of total assets in 2025, a decrease from 94.5% in 2014.
- Cash Position: Cash and equivalents constituted 42.2% of total assets in 2025, up from 27.1% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, an increase from 0.0% in 2014.
- Asset Diversification: The largest asset category is inventory at 23.2% of total assets.
Crescita Therapeutics Inc Competitors by Total Assets
Key competitors of Crescita Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs585.02 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
China | CN¥10.37 Billion |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
|
China | CN¥7.28 Billion |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS
|
USA | $392.01 Million |
|
Procter & Gamble Health Limited
NSE:PGHL
|
India | Rs8.94 Billion |
Crescita Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.33 | 2.77 | 3.92 |
| Quick Ratio | 2.33 | 2.04 | 3.23 |
| Cash Ratio | 0.00 | 1.68 | 0.00 |
| Working Capital | CA$11.00 Million | CA$9.79 Million | CA$14.82 Million |
Crescita Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Crescita Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.91 |
| Latest Market Cap to Assets Ratio | 0.52 |
| Asset Growth Rate (YoY) | -6.6% |
| Total Assets | CA$20.33 Million |
| Market Capitalization | $10.64 Million USD |
Valuation Analysis
Below Book Valuation: The market values Crescita Therapeutics Inc's assets below their book value (0.52x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Crescita Therapeutics Inc's assets decreased by 6.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Crescita Therapeutics Inc (2014–2025)
The table below shows the annual total assets of Crescita Therapeutics Inc from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CA$20.33 Million ≈ $14.70 Million |
-6.65% |
| 2024-12-31 | CA$21.78 Million ≈ $15.75 Million |
-11.47% |
| 2023-12-31 | CA$24.60 Million ≈ $17.79 Million |
-13.64% |
| 2022-12-31 | CA$28.48 Million ≈ $20.60 Million |
-1.52% |
| 2021-12-31 | CA$28.92 Million ≈ $20.92 Million |
+7.80% |
| 2020-12-31 | CA$26.83 Million ≈ $19.41 Million |
-0.02% |
| 2019-12-31 | CA$26.84 Million ≈ $19.41 Million |
-2.64% |
| 2018-12-31 | CA$27.57 Million ≈ $19.94 Million |
+22.16% |
| 2017-12-31 | CA$22.57 Million ≈ $16.32 Million |
-47.55% |
| 2016-12-31 | CA$43.02 Million ≈ $31.12 Million |
+3521.04% |
| 2015-12-31 | CA$1.19 Million ≈ $859.38K |
-27.38% |
| 2014-12-31 | CA$1.64 Million ≈ $1.18 Million |
-- |
About Crescita Therapeutics Inc
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. It operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The company owns proprietary drug delivery platforms, which include Multiplexed Molecular Penetration Enhanc… Read more